| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CALY |
| Uniprot No | Q9NYX4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-217aa |
| 氨基酸序列 | MVKLGCSFSGKPGKDPGDQDGAAMDSVPLISPLDISQLQPPLPDQVVIKTQTEYQLSSPDQQNFPDLEGQRLNCSHPEEGRRLPTARMIAFAMALLGCVLIMYKAIWYDQFTCPDGFLLRHKICTPLTLEMYYTEMDPERHRSILAAIGAYPLSRKHGTETPAAWGDGYRAAKEERKGPTQAGAAAAATEPPGKPSAKAEKEAARKAAGSAAPPPAQ |
| 预测分子量 | 23,4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CALY(Calcyon)重组蛋白的3篇参考文献示例(注：文献信息为虚构示例，真实文献请通过学术数据库查询)：
1. **《重组CALY蛋白在神经信号传导中的功能研究》**
- 作者：Smith J, et al.
- 摘要：研究通过重组表达CALY蛋白，发现其作为多巴胺受体辅助因子，调控神经元内吞作用，可能参与精神疾病的病理机制。
2. **《CALY重组蛋白的晶体结构解析及其与配体相互作用》**
- 作者：Chen L, et al.
- 摘要：利用X射线晶体学解析CALY重组蛋白的三维结构，揭示其钙离子结合域的结构特征，为靶向药物设计提供依据。
3. **《大肠杆菌表达系统高效制备功能性CALY重组蛋白》**
- 作者：Wang Y, et al.
- 摘要：优化大肠杆菌表达条件，成功获得高纯度CALY重组蛋白，并验证其在体外模型中维持生物学活性，适用于后续分子互作研究。
建议通过PubMed、Google Scholar等平台以“Calcyon recombinant protein”或“CALY protein expression”为关键词检索真实文献。
CALY (Calcyon) is a neuron-enriched transmembrane protein implicated in dopaminergic and glutamatergic signaling pathways. Initially identified as a binding partner of the D1 dopamine receptor, it plays a regulatory role in clathrin-mediated endocytosis and receptor recycling, influencing synaptic plasticity. Structurally, CALY contains an N-terminal EF-hand calcium-binding domain, a central coiled-coil region, and a C-terminal PDZ-binding motif, enabling interactions with multiple synaptic proteins like PSD-95 and GRIP1. Its calcium-sensing capacity links intracellular Ca²⁺ fluctuations to vesicle trafficking, modulating neurotransmitter release and postsynaptic receptor density.
Research highlights CALY's involvement in cognitive functions, with dysregulation observed in neuropsychiatric disorders. Altered CALY expression correlates with schizophrenia, attention deficit hyperactivity disorder (ADHD), and addiction, potentially due to disrupted dopamine-glutamate crosstalk. In Alzheimer's disease models, CALY overexpression exacerbates amyloid-β toxicity by promoting endocytosis of amyloid precursor protein (APP), suggesting a pathogenic role.
Recombinant CALY protein is typically produced using bacterial (e.g., E. coli) or mammalian expression systems, often tagged with fluorescent markers or purification handles (e.g., His-tag) for experimental tracking. Studies employ it to investigate protein-protein interactions, receptor trafficking mechanisms, and calcium-dependent signaling cascades. It also serves as an antigen for antibody development and a tool for high-throughput drug screening targeting neuropsychiatric conditions. Recent work explores CALY's potential as a biomarker or therapeutic target, particularly in disorders involving dopamine dysfunction. However, its pleiotropic roles and tissue-specific isoforms necessitate further structural and functional characterization.
×
